Nxera Pharma Co.,Ltd. [4565.T]
TOKYO, May 01 (Pulse News Wire) – Nxera Pharma CO.,LTD. (4565.T) reported strong progress across its operations for the quarter ending March 31, 2026.
The company signed a significant contract with Sunsera Pharmaceuticals to deliver vamorolone to Duchenne muscular dystrophy patients in Japan and APAC regions. Additionally, Nxera's spin-off company, Orexia, was acquired by Eli Lilly and Company for up to ¥11.60 billion, solidifying the company’s strategic growth initiatives and reinforcing its financial position. In the first quarter of fiscal year 2026, Nxera recorded a revenue increase of ¥11.26 billion compared to the same period last year, driven by seven milestone achievements.
Research and development expenses decreased by ¥780 million due to cost optimization efforts and reduced clinical program costs. Operating income improved significantly to ¥3.244 billion from a loss of ¥2.193 billion in the previous year's quarter. Nxera also highlighted several advancements in its pipeline, including the initiation of Phase 2 trials for multiple drug candidates targeting neurological disorders such as schizophrenia and Alzheimer's disease.
The company continues to expand its partnerships and secure milestones, positioning itself for sustained growth and value creation for shareholders.
🟢 Confidence: High AI-translated content.